MedTrace Logo

Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis

NCT05363449 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2024-04-10

No results posted yet for this study

Summary

This Phase 1 study has been designed to determine the safety, tolerability and pharmacokinetics (PK) of UHE 103 Cream compared to Naftin Cream, 2% under maximal use conditions for 2 weeks treatment in subjects with tinea cruris and/or tinea pedis

Conditions

  • Tinea Cruris
  • Tinea Pedis

Interventions

DRUG

UHE-103 Cream

UHE-103 is an investigational combinational therapy containing keratolytic and antifungal

DRUG

Naftin (naftifine hydrochloride) Cream

Naftin (naftifine hydrochloride) Cream, 2%. Topical cream containing active drug

Sponsors & Collaborators

  • Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Tony Andrasfay · Therapeutics Inc. (CRO)

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-17
Primary Completion
2023-11-14
Completion
2023-11-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05363449 on ClinicalTrials.gov